ALA-101

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameALA-101
Drug Alias NameCAR 19-iNKTALA-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSolid tumoursLymphoma, Non-HodgkinLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArovella Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesArovella Therapeutics LtdImugene Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, Non-HodgkinLymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A